On August 20, Tempus AI rose 5.01% in regular trading, trading at $65.57/share, with turnover of $174 million, extending a multi-day rally that saw the stock surge over 12% in the prior session.

The sustained upward momentum follows the company's Q2 earnings report, which significantly exceeded expectations. Tempus AI posted an adjusted loss of $0.04 per share versus the consensus estimate of a $0.14 loss, representing a 71% beat. Revenue reached $382.5 million, up from $314.6 million a year earlier, surpassing the $379.7 million estimate. The company also raised its full-year revenue guidance to $1.60-$1.61 billion, above the analyst consensus of $1.59 billion.

Additionally, the company's announced $1.5 billion acquisition of Personalis continues to support investor sentiment, as the deal integrates molecular residual disease detection capabilities into Tempus AI's precision oncology platform.

Within the Life Sciences Tools & Services sector, Personalis rose 6.7%, Illumina gained 2.31%, Danaher added 0.94%, Thermo Fisher Scientific rose 0.61%, while Waters declined 0.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)